key: cord-1000103-r2xd12s6
authors: Nasri, Elahe; Shoaei, Parisa; Vakili, Bahareh; Mirhendi, Hossein; Sadeghi, Somayeh; Hajiahmadi, Somayeh; Sadeghi, Alireza; Vaezi, Afsane; Badali, Hamid; Fakhim, Hamed
title: Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran
date: 2020-10-03
journal: Mycopathologia
DOI: 10.1007/s11046-020-00493-2
sha: 8608e222c7b11500e165b03dd4b91cacca2d60b4
doc_id: 1000103
cord_uid: r2xd12s6

Although patients with severe immunodeficiency and hematological malignancies has been considered at highest risk for invasive fungal infection, patients with severe pneumonia due to influenza, and severe acute respiratory syndrome coronavirus (SARS-CoV) are also at a higher risk of developing invasive pulmonary aspergillosis (IPA). Recently, reports of IPA have also emerged among SARS-CoV-2 infected patients admitted to intensive care units (ICUs). Here, we report a fatal case of probable IPA in an acute myeloid leukemia patient co-infected with SARS-CoV-2 and complicated by acute respiratory distress syndrome (ARDS). Probable IPA is supported by multiple pulmonary nodules with ground glass opacities which indicate halo sign and positive serum galactomannan results. Screening studies are needed to evaluate the prevalence of IPA in immunocompromised patients infected with SARS-CoV-2. Consequently, testing for the presence of Aspergillus in lower respiratory secretions and galactomannan in consecutive serum samples of COVID-19 patients with timely and targeted antifungal therapy based on early clinical suspicion of IPA are highly recommended.

Invasive fungal infections (IFIs) are life-threatening opportunistic infections, and immunosuppressed patients those with hematological malignancies have been considered at highest risk for developing IFIs [1] [2] [3] [4] [5] [6] . Serious viral pulmonary infections are associated with increased risk for superinfections, including invasive pulmonary aspergillosis (IPA) in immunocompromised patients, particularly in those with hematological malignancies [1, 2] . The prevalence of IPA in critically ill patients with acute respiratory distress syndrome (ARDS) is approximately 23% and an estimated mortality rate of more than 50% [1, 3] . Studies have revealed that influenza A and respiratory syncytial virus (RSV) were the most prevalent coinfecting respiratory viruses, and patients with viral co-infections have higher mortality rates than those with IPA alone [3, 6, 7] . Corona virus disease 2019 , caused by SARS-CoV-2, arose in late 2019 with rapid global spread. There have also been a number of reports of patients with probable or possible COVID-19 associated pulmonary aspergillosis [1] [2] [3] [4] 8] . Respiratory alveolar damage and abnormal mucociliary clearance caused by this virus may facilitate fungal invasion [2] , and half of the IPA/ SARS-CoV-2 co-infections occur in non-neutropenic hospitalized patients in the intensive care unit (ICU) [2] . However, reports such co-infections in patients with hematologic malignancies are currently limited. Here, we report a case of COVID-19 pneumonia in an acute myeloid leukemia patient with probable invasive pulmonary aspergillosis.

In March 2020, a 42-year-old female with a history of diabetes was hospitalized (day 0) in the Hematology-Oncology ward, Omid hospital, Isfahan, Iran, with newly diagnosed non-M3 acute myeloid leukemia (AML), and began standard combination chemotherapy with idarubicin and cytarabine (day 2). She also received metformin 500 mg/day for diabetes. Laboratory results prior to chemotherapy showed leukocytosis, anemia, and thrombocytopenia (Table 1) . Following chemotherapy, she became febrile with a dry cough, dyspnea, and myalgia which lasted 2 days without hemoptysis, coryza, sore throat, pleuritic chest pain, or cyanosis (day 6). She complained of no other symptoms, nor had a history of travel or contact with known or suspected COVID-19 patients. However, she had been hospitalized for the prior two weeks due to weakness and anal bleeding. Physical examination (day 8) revealed a body temperature of 38.7°C, blood pressure of 100/70 mm Hg, a pulse of 109 beats per minute, respiratory rate of 22 breaths per minute, and oxygen saturation of 91% while the patient was breathing ambient air. The patient had some red spots and petechiae on the soft palate and both legs. Supplemental oxygen, delivered by nasal cannula at 4 L per minute was administered. Lung auscultation revealed rhonchi and examination of her heart revealed no murmurs, rubs, or gallops. The neurological examination and abdominal examination was unremarkable. Nasopharyngeal and oropharyngeal swabs were obtained; however, nucleic acid amplification test for influenza A and B was negative. Realtime reverse-transcriptase-polymerase-chain-reaction (rRT-PCR) by Roter-Gene Q 6000 (Qiagen, Hilden, Germany) for SARS-CoV-2 targeting the N gene and ORF1ab gene (Sansure, China) was positive. Blood and urine cultures were sterile. An arterial blood gas demonstrated a pH of 7.55, PaO 2 49 mm Hg, PCO 2 38.6 mm Hg, HCO 3 29.3 mmol/L and the patient underwent oxygen supplementation. The high-resolution chest-computed tomography (CT) scan on day 8 demonstrated multiple vessel-related nodular opacities with grand glass halo including central and peripheral distribution, bilateral pleural effusion (Fig. 1) . The patient was rehydrated with approximately 2 L of normal saline over the first 2 days of hospitalization. Following chemotherapy, laboratory results were notable for persistent leukopenia, anemia, and thrombocytopenia (Table 2) . Empirical antibacterial therapy consisting of linezolid 600 mg bid plus meropenem 3 g/d, lopinavir/ritonavir 400/100 mg bid, and interferon Beta-1b 0.25 mg SQ every 48 h for three dosages was started. On day 9 the nasal cannula was changed to non-invasive positive pressure (Table 2) . Chest-computed tomography (CT) revealed multiple nodular opacities with grand glass halo consisting of central and peripheral distribution (Fig. 1) , and based on these results and the positive serum GM results, a diagnosis of probable invasive pulmonary aspergillosis with COVID-19 pneumonia was made. Therefore, intravenous liposomal amphotericin B 5 mg/kg/day was initiated. Despite antifungal and antibacterial therapy, the patient's condition continued to deteriorate, and the patient died the morning of day 12 due to respiratory and hemodynamic instability (Fig. 2 ).

As of September 17, 2020, the COVID-19 pandemic due to SARS-CoV-2 has thus far killed over 23,808 people and infected over 413,149 individuals in Iran.

Recent studies have shown that COVID-19 associated pulmonary aspergillosis (CAPA) may occur, especially in critically ill patients [2, 6] . We report the first probable case of aspergillosis in an acute myeloid leukemia patient with COVID-19 associated with severe ARDS in Iran. Immediately after chemotherapy, the patient became neutropenic, interestingly the maximal reductions in neutrophil counts typically occur 6-14 days after conventional doses of anthracyclines, antifolates, and antimetabolites [9] . CT scan is an important imaging modality assisting in the diagnosis and management of patients with COVID-19. IPA is a possible complication of critically ill patients with ARDS due to COVID-19 [1] [2] [3] [4] 10] . Putative IPA was found in nearly 33% of mechanically ventilated patients with influenza or COVID-19 even in the absence of previous immune disorders [3, 10] . In previous outbreaks of SARS, proven invasive pulmonary aspergillosis were reported [11] . Serum GM screening detects a polysaccharide antigen found principally in the cells walls of Aspergillus species, and this assay is a sensitive diagnostic marker (70%) in neutropenic patients [2, 8] and also positive in this case. As bronchoscopy generates aerosols that cause considerable risk to health care workers, and due to thrombocytopenia in this patient, it was not performed, and GM testing is a suitable diagnostic assay for IPA in lower respiratory tract specimens. The European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria for invasive aspergillosis are appropriate for hematologic malignancy patients, and our patient was considered to have probable IPA based on an abnormal CT scan of the lungs and serum GM results, in addition to the typical COVID-19 attributed lesions [12] . In contrast, Alanio et al. reported a case of a patient with myeloma who presented with probable IPA with one nodule on chest X-rays in addition to the typical COVID-19 attributed lesions along with a positive bronchoalveolar lavage (BAL) culture, but a negative Aspergillus quantitative real-time PCR and serum galactomannan test [6] . In addition, Rutsaert et al. reported patient with AML who had developed IPA during chemotherapy with A. fumigatus growth in BAL culture, although a CT scan and histological examination were not available [13] . Due to challenges in the diagnosis of IPA in critically ill patients with COVID-19, clinicians should maintain a high level of suspicion for this invasive mycosis [1, 6] . Consequently, GM test is simple, and the specificity of an ODI-cutoff of [ 1.0 is about 90% to detect IPA [14] . Detection of GM has contributed substantially to the diagnosis of probable IA and is validated in a variety of patient groups, particularly with serial measurements [15] [16] [17] [18] . Studies have suggested a sensitivity as high as 89% and a specificity of 92% in high-risk HSCT patients not receiving anti-mold prophylaxis, and a meta-analysis using an optical density index cutoff of C 0.5 showed a sensitivity of 78% and a specificity of 81%. Serial assessments of GM may also offer prognostic value in predicting clinical outcomes [15] [16] [17] [18] . The AML patient reported here had classical risk factors for IPA, and it is well known that viral infections, such as severe COVID-19 pneumonia, are associated with immune dysregulation (both T-helper cell 2 (Th2) and Th1, impaired cellmediated immune response and increase the risk for IPA [2, 19] . Despite antifungal therapy, the patient died due to respiratory distress and pulmonary failure. Our case report highlights that clinical suspicion and screening are needed to evaluate the prevalence of IPA in immunocompromised patients infected with COVID-19. Co-infection with Aspergillus may lead to poor outcomes, especially in hematological malignancies patients. Therefore, testing for the presence of Aspergillus in lower respiratory secretions and GM in consecutive serum samples in COVID-19 patients and early clinical suspicion of IPA with timely and targeted antifungal therapy according to national and international guidelines are highly recommended.

COVID-19-associated invasive pulmonary Aspergillosis

Invasive pulmonary Aspergillosis complicating COVID-19 in the ICU-A case report. Med Mycol Case Rep

Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. Mycopathologia

Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China

COVID-19 associated invasive candidiasis

Prevalence of putative invasive pulmonary Aspergillosis in critically ill patients with COVID-19

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report

Harrison's principles of internal medicine

COVID-19 associated pulmonary Aspergillosis

Fatal Aspergillosis in a patient with SARS who was treated with corticosteroids

Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

COVID-19-associated invasive pulmonary Aspergillosis

Invasive pulmonary aspergillosis in severe COVID-19 pneumonia

Serum galactomannan-based early detection of invasive Aspergillosis in hematology patients receiving effective antimold prophylaxis

Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive Aspergillosis: variables that affect performance

Prospective clinical evaluation of lower cut-off for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients

Galactomannan detection for invasive Aspergillosis in immunocompromized patients

Diagnosing COVID-19-associated pulmonary Aspergillosis

Acknowledgements This study was financially supported by a grant from the School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran (No. 198338) which we gratefully acknowledge. The authors acknowledge Prof. Nathan P. Wiederhold for his comments on the manuscript and for careful editing.Funding This study was supported by grants from the Emergency special program for COVID-19 of Isfahan University of Medical Sciences, Isfahan, Iran project (No. 198338).

Conflict of interest The authors report no conflicts of interest.Informed Consent Informed consent was obtained from the patient for publication of this case report and accompanying image.